Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0557 · 5 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | OTHER | MK0557 10mg tablet qd, crossing over to MK0557 Pbo tablet qd. |
| 2 | OTHER | MK0557 Pbo tablet qd, crossing over to MK0557 10mg tablet qd. |
| Name | Type | Description |
|---|---|---|
| MK0557 | DRUG | - |
| Comparator: Placebo (unspecified) | DRUG | MK0557 Pbo tablet qd for a 15-wk treatment period |
Inclusion Criteria: * Obese men and nonpregnant women between the ages of 18 and 65 years with a body mass index (height to weight ratio) as required by the study. Exclusion Criteria: * Patients with uncontrolled high blood pressure and/or diabetes mellitus (high blood sugar)
Top 20 of 32 competitors
MK0557 is an investigational small molecule being developed by Merck & Company, Inc. (MRK) for the treatment of obesity and paranoid schizophrenia. It is in Phase 3 clinical development for obesity, with completed trials in this indication. The drug is not approved and remains under clinical investigation.
MK0557 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials of this investigational small molecule for obesity and paranoid schizophrenia. Merck is responsible for the drug's development and clinical testing.
MK0557 is in Phase 3 clinical development for obesity. It has completed four clinical trials, including two Phase 3 studies and two Phase 2 studies, all in obese patients. The drug remains investigational and is not yet approved for any use.
MK0557 has completed four clinical trials. These include NCT00092859, a 2-year Phase 3 study in 1500 obese patients; NCT00092872, a 1-year Phase 3 study in 359 obese patients; NCT00533481, a Phase 2 combination study with sibutramine or orlistat in 497 patients; and NCT00533598, a Phase 2 study in obese subjects.
MK0557 is a distinct investigational drug developed by Merck. It has been studied alone and in combination with other weight-loss medications like sibutramine and orlistat in clinical trials. No alternative names for MK0557 have been reported in the available trial data.